Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single-institute study

摘要: BACKGROUND Integration of mutational profiling to identify driver genetic alterations in a clinical setting is necessary facilitate personalized lung cancer medicine. A tumor genotyping panel was developed and the Shizuoka Lung Cancer Mutation Study initiated as prospective study. This study reports frequency Japanese adenocarcinoma patients, clinicopathologic correlations with each genotype. METHODS Between July 2011 January 2013, 411 patients admitted Center were included this their written informed consent. Surgically resected tissues, biopsies, and/or body cavity fluids collected tested for 23 hotspot sites mutations 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN, HER2), gene amplifications 5 MET, FGFR1, FGFR2), ALK, ROS1, RET fusions. RESULTS Genetic detected 54.3% (223 411) all patients. The most common EGFR (35.0%) followed by KRAS (8.5%) ALK fusions (5.0%). Concurrent 22 (5.4%), observed 16 partner concurrent alteration. Significantly more older patients. CONCLUSIONS This one largest on adenocarcinoma. These data suggest that using multimutational testing platform would be valuable expanding range molecular-targeted therapeutics cancer. 2014;120:1471–1481. © 2014 American Society.